Suppliers and packagers for LAMISIL

LAMISIL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Karo Hlthcare	LAMISIL	terbinafine hydrochloride	CREAM;TOPICAL	020980	NDA	Voyant Beauty Inc.	61047-120-03	1 TUBE in 1 CARTON (61047-120-03) / 30 g in 1 TUBE	2020-02-20
Karo Hlthcare	LAMISIL	terbinafine hydrochloride	CREAM;TOPICAL	020980	NDA	Voyant Beauty, Inc.	61047-139-01	1 TUBE in 1 CARTON (61047-139-01) / 30 g in 1 TUBE	2024-08-21
Karo Hlthcare	LAMISIL	terbinafine hydrochloride	CREAM;TOPICAL	020980	NDA	Voyant Beauty, Inc.	61047-139-02	1 TUBE in 1 CARTON (61047-139-02) / 12 g in 1 TUBE	2024-08-21
Karo Hlthcare	LAMISIL	terbinafine hydrochloride	CREAM;TOPICAL	020980	NDA	Karo Healthcare Inc.	84485-3607-1	1 TUBE in 1 CARTON (84485-3607-1) / 12 g in 1 TUBE	2025-01-20
Karo Hlthcare	LAMISIL	terbinafine hydrochloride	CREAM;TOPICAL	020980	NDA	Karo Healthcare Inc.	84485-3748-3	1 TUBE in 1 CARTON (84485-3748-3) / 30 g in 1 TUBE	2024-11-01
Karo Hlthcare	LAMISIL	terbinafine hydrochloride	CREAM;TOPICAL	020980	NDA	Karo Healthcare Inc.	84485-4030-1	1 TUBE in 1 CARTON (84485-4030-1) / 12 g in 1 TUBE	2025-10-09

LAMISIL (Terbinafine Hydrochloride) Manufacturing Supply Chain

Last updated: February 19, 2026

This report analyzes the key suppliers and manufacturing landscape for LAMISIL (terbinafine hydrochloride), a synthetic allylamine antifungal. The supply chain involves active pharmaceutical ingredient (API) manufacturers and formulation producers. Key market participants and their roles are identified, alongside regulatory considerations impacting production.

Who Manufactures the Active Pharmaceutical Ingredient (API) for LAMISIL?

The primary API for LAMISIL is terbinafine hydrochloride. Production is concentrated among a limited number of global manufacturers, primarily in China and India, which dominate the generic API market.

• Key API Suppliers:

  • Novartis (Original Innovator): While Novartis developed LAMISIL, its API manufacturing strategy for the branded product has evolved. For generic production, reliance shifts to third-party API suppliers.
  • Major Generic API Manufacturers: Companies such as Zhejiang Huahai Pharmaceutical Co., Ltd. (China) and Dr. Reddy's Laboratories (India) are significant producers of terbinafine hydrochloride API. These companies supply to multiple generic drug manufacturers globally.
  • Other Asian Manufacturers: A substantial portion of API production is also undertaken by smaller to medium-sized manufacturers in China and India, often operating as contract manufacturers. Specific company names are subject to change and commercial agreements, but the geographic concentration remains consistent.

• Production Capacity and Lead Times:

  • Capacity varies significantly among suppliers, with larger players capable of producing metric tons of API annually.
  • Lead times for API orders typically range from 8 to 16 weeks, depending on the supplier's existing production schedule, order volume, and raw material availability. Urgent requirements may incur premium pricing and expedited production slots.

• Quality Control and Regulatory Compliance:

  • API manufacturers must adhere to Good Manufacturing Practices (GMP) as stipulated by major regulatory bodies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others.
  • Certificates of Analysis (CoA) are mandatory for each batch, detailing purity, impurity profiles, and physical characteristics.
  • Site inspections by regulatory agencies and audits by pharmaceutical companies are common.

What are the Key Formulation Manufacturers for LAMISIL Products?

Formulation manufacturing transforms the terbinafine hydrochloride API into finished dosage forms, such as tablets, creams, and sprays. This segment is more fragmented due to the large number of generic drug companies.

• Branded LAMISIL (Novartis): Novartis retains its own manufacturing facilities or utilizes contract manufacturing organizations (CMOs) for its branded LAMISIL products. Specific plant locations are proprietary but are distributed globally to serve major markets.

• Generic LAMISIL Manufacturers: This segment is highly competitive and includes numerous companies that produce generic terbinafine hydrochloride products. Examples include:

  • Major Pharmaceutical Companies: Teva Pharmaceutical Industries, Mylan (now part of Viatris), Sandoz (Novartis' generics division), and Aurobindo Pharma are prominent players in the global generic drug market and produce terbinafine hydrochloride formulations.
  • Regional Generic Manufacturers: Numerous smaller to medium-sized pharmaceutical companies in North America, Europe, and Asia also manufacture and market generic LAMISIL. These often focus on specific regional markets.

• Dosage Forms Manufactured:

  • Tablets: The most common dosage form for oral administration. Manufacturers produce various strengths (e.g., 125 mg, 250 mg).
  • Creams and Gels: For topical treatment of fungal infections. Strengths typically range from 1% to 2%.
  • Sprays: An alternative topical formulation for ease of application.

• Contract Manufacturing Organizations (CMOs): Many generic companies outsource formulation and packaging to specialized CMOs to manage production costs and capacity. Companies like Patheon (part of Thermo Fisher Scientific), Catalent, and Unither Pharmaceuticals are examples of CMOs that may be involved in producing terbinafine hydrochloride formulations.

What Raw Materials and Intermediates are Essential for Terbinafine Hydrochloride Synthesis?

The synthesis of terbinafine hydrochloride involves several key chemical intermediates and raw materials. The supply chain for these precursors is critical for consistent API production.

• Key Chemical Intermediates:

  • N-methyl-1-naphthylmethylamine: A primary building block for the terbinafine molecule.
  • 3-Phenylpropionitrile: Another crucial intermediate in the synthetic pathway.
  • Various reagents and solvents: Including organometallic reagents, acids, bases, and organic solvents (e.g., methanol, ethanol, toluene).

• Sourcing of Raw Materials:

  • The upstream supply chain for these intermediates is primarily located in Asia, with China being a dominant source for specialty chemicals and fine chemical intermediates.
  • Global chemical suppliers and specialized fine chemical manufacturers produce these materials. The purity and consistency of these inputs directly impact the final API quality.
  • Supply chain disruptions, geopolitical factors, and environmental regulations in producing regions can affect availability and pricing.

• Supplier Due Diligence:

  • API manufacturers conduct rigorous due diligence on their raw material suppliers, including quality audits and verification of compliance with relevant chemical safety and environmental standards.
  • Dual sourcing strategies are often employed to mitigate risks associated with single-supplier dependency.

What are the Regulatory Considerations for LAMISIL Manufacturing?

Manufacturing of both API and finished drug products is heavily regulated to ensure safety, efficacy, and quality.

• Good Manufacturing Practices (GMP):

  • All manufacturing facilities, both for API and finished dosage forms, must comply with current GMP guidelines (cGMP).
  • Regulatory bodies (FDA, EMA, PMDA, etc.) conduct inspections to verify compliance.
  • Documentation, process validation, and quality management systems are paramount.

• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs):

  • API manufacturers submit DMFs (in the US) or ASMFs (in Europe) to regulatory agencies. These confidential documents contain detailed information about the API manufacturing process, quality control, and stability.
  • Formulation manufacturers reference these DMFs/ASMFs in their drug product applications.

• Marketing Authorization Applications (MAA) / New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDA):

  • Finished product manufacturers must obtain marketing authorization from relevant health authorities. This requires submission of comprehensive data on the drug product's quality, safety, and efficacy (for new drugs) or bioequivalence (for generics).
  • The API supplier and its DMF/ASMF are critical components of these applications.

• Pharmacopoeial Standards:

  • Terbinafine hydrochloride API and finished products must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).

• Post-Market Surveillance:

  • Manufacturers are responsible for ongoing monitoring of product quality and safety, including adverse event reporting and potential recalls.

What are the Key Trends in the LAMISIL Supply Chain?

The LAMISIL supply chain is influenced by broader trends in the pharmaceutical industry, particularly in the generics sector.

• Globalization of API Production:

  • Continued concentration of API manufacturing in cost-competitive regions like China and India. This drives down API costs but also introduces supply chain complexity and geopolitical risks.

• Increasing Demand for Generics:

  • Growing market for generic terbinafine hydrochloride products due to patent expirations and healthcare cost containment measures. This fuels demand for API from multiple generic manufacturers.

• Supply Chain Resilience and Risk Management:

  • Increased focus on supply chain diversification and resilience, particularly following disruptions caused by pandemics or geopolitical events. Companies are exploring near-shoring or multi-sourcing strategies.

• Stringent Regulatory Scrutiny:

  • Heightened regulatory oversight and inspection frequency by global health authorities. This necessitates robust quality systems and continuous compliance efforts from all supply chain partners.

• Technological Advancements in Synthesis:

  • Ongoing efforts to optimize synthetic routes for terbinafine hydrochloride to improve yield, reduce costs, and minimize environmental impact. This can lead to shifts in preferred intermediates and suppliers.

Key Takeaways

The manufacturing of LAMISIL (terbinafine hydrochloride) relies on a globalized supply chain. The Active Pharmaceutical Ingredient (API) is predominantly produced by specialized manufacturers in China and India, with a significant number of generic drug companies formulating the API into finished dosage forms worldwide. Contract Manufacturing Organizations (CMOs) play a crucial role in formulation and packaging. Raw material sourcing for API synthesis is also largely concentrated in Asia. Regulatory compliance, particularly adherence to Good Manufacturing Practices (GMP) and submission of comprehensive drug master files, is essential at every stage of the supply chain. Key trends include the ongoing globalization of API production, increased demand for generics, and a heightened focus on supply chain resilience and regulatory compliance.

FAQs

1. Who are the primary global suppliers of terbinafine hydrochloride API?

The primary global suppliers of terbinafine hydrochloride API are concentrated in China and India. Major generic API manufacturers like Zhejiang Huahai Pharmaceutical Co., Ltd. and Dr. Reddy's Laboratories are significant producers, alongside a number of other specialized chemical manufacturers in these regions.

2. How does Novartis manage its LAMISIL API supply for the branded product?

Novartis, as the original innovator, manages its LAMISIL API supply through a combination of in-house manufacturing capabilities and contracted third-party API suppliers. For generic versions, the market relies on the aforementioned generic API manufacturers.

3. What are the common dosage forms for LAMISIL and who manufactures them?

Common dosage forms for LAMISIL include tablets (e.g., 125 mg, 250 mg) for oral use and creams/gels (e.g., 1% or 2%) and sprays for topical application. A wide range of generic pharmaceutical companies, including Teva, Viatris, Sandoz, and Aurobindo Pharma, along with numerous regional manufacturers, produce these formulations, often utilizing contract manufacturing organizations (CMOs).

4. What regulatory documentation is required for terbinafine hydrochloride API?

Terbinafine hydrochloride API manufacturers must adhere to Good Manufacturing Practices (GMP) and submit regulatory documentation such as Drug Master Files (DMFs) in the U.S. or Active Substance Master Files (ASMFs) in Europe. These files detail the manufacturing process, quality controls, and stability data to regulatory agencies.

5. What are the potential risks in the LAMISIL supply chain?

Potential risks in the LAMISIL supply chain include geopolitical instability in key manufacturing regions (China, India), raw material price volatility, supply chain disruptions due to unforeseen events (e.g., pandemics, natural disasters), increased regulatory scrutiny leading to production halts, and quality control failures from API or formulation manufacturers.

6. How do pharmacopoeial standards affect LAMISIL manufacturing?

Pharmacopoeial standards, such as those set by the USP, Ph. Eur., and JP, dictate the required purity, impurity limits, and physical characteristics for both terbinafine hydrochloride API and its finished dosage forms. Manufacturers must ensure their products consistently meet these stringent standards to gain and maintain market approval.

7. What is the typical lead time for ordering terbinafine hydrochloride API?

Typical lead times for ordering terbinafine hydrochloride API range from 8 to 16 weeks, depending on the supplier's existing production schedule, the volume of the order, and the availability of necessary raw materials. Expedited orders may be possible but usually come with higher costs.

8. How does the rise of generic LAMISIL impact API demand?

The increasing prevalence of generic LAMISIL products, driven by patent expirations and healthcare cost pressures, directly fuels higher demand for terbinafine hydrochloride API from multiple generic drug manufacturers, creating a competitive market for API suppliers.

9. What role do Contract Manufacturing Organizations (CMOs) play in LAMISIL production?

CMOs play a significant role, particularly in the formulation and packaging of generic LAMISIL products. Many pharmaceutical companies outsource these manufacturing steps to specialized CMOs to manage production capacity, reduce costs, and leverage specialized expertise.

10. How are supply chain disruptions mitigated by LAMISIL manufacturers?

Manufacturers mitigate supply chain disruptions through strategies such as dual sourcing for critical raw materials and APIs, maintaining safety stock inventories, diversifying manufacturing locations where feasible, and establishing robust quality agreements with all supply chain partners to ensure consistent standards and proactive issue resolution.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from https://www.fda.gov/ [2] European Medicines Agency. (n.d.). Guidance Documents. Retrieved from https://www.ema.europa.eu/ [3] United States Pharmacopeia. (n.d.). USP-NF. Retrieved from https://www.usp.org/ [4] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/ [5] News articles and industry reports from pharmaceutical and chemical trade publications (e.g., C&EN, Fierce Pharma, Pharma Manufacturing). (Specific articles not cited as general industry knowledge.) [6] Company websites of key API and formulation manufacturers (e.g., Novartis, Teva, Dr. Reddy's Laboratories, Zhejiang Huahai Pharmaceutical, Aurobindo Pharma). (Specific URLs not cited as general industry information access.)